Member Info for EmeraldCarrots

Posts. It's really quite amusing.

We will see......

Moab

" I see no reason why Parsortix could not be used to help detect the HER-2 levels in all cancer types."

Reason: I think you will find that HER status applies only to breast cancer.".

============================================

Incorrect. The Astrazeneca RNS just yesterday (see link below) names many cancers as you can see:-

"HER2-directed therapies have been used to treat breast, gastric, lung and colorectal cancers for a number of years.3,6,7 Although HER2 is expressed in solid tumour types including biliary tract, bladder, cervical, endometrial, ovarian and pancreatic cancers, testing is not routinely performed in these additional tumour types and as a result, available literature is limited.4 In these solid tumours, HER2-positive expression, classified as immunohistochemistry (IHC) 3+, has been observed at rates from 1% to 28%.8,9 Approximately 1% to 5% of patients with NSCLC have tumours with HER2 overexpression (IHC 3+), however, the levels of protein expression reported vary in the literature.8,10 Approximately 1% to 4% of patients with metastatic colorectal cancer have tumours which are HER2 overexpressing (IHC 3+).8,11,12

https://www.lse.co.uk/rns/AZN/enhertu-approved-in-us-for-her2-solid-tumours-d992ucbs0xpl3ik.html

All IMHO.

New York, February 10, 2022.

Note these are just the trials that include a PD1/PDL1-targeting agent.....................

"The number of clinical trials started each year that include a PD1/PDL1-targeting agent has continued to increase, currently at 5,683 worldwide, up 278% from the number of trials reported in 2017.".

https://www.cancerresearch.org/media-room/2022/pd1-pdl1-clinical-trials-combo-mono

"Breast cancer is the most common cancer worldwide. There were more than 2.26 million new cases of breast cancer in women in 2020."

https://www.wcrf.org/cancer-trends/breast-cancer-statistics/

Hopester.

"Would I be right in thinking that since Enhertu is tumour agnostic and the only information required for successful treatment is the tumour HER2 status, that Parsortix could be applied to CTC detection in all cancer types?".

===========================

The Parsortix machine can catch circulating tumour cells (CTC's) of all cancer types as I understand it. In fact the blood sample can even be from other animals. Then for **cancer drug trials** the captured cells can be tested for their HER-2 status. However Parsortix, thus far, is only approved in the USA for catching ***Breast Cancer*** CTC's for analysis at what you might call cancer clinic level. For the other cancer types it can only be used in the USA during cancer drug trials. Having said that there is a huge World market for Breast Cancer treatment and a huge World wide market for drug trials. The numbers are staggering. So in time, after more FDA approvals are sought for other types of cancer and hopefuly got, I see no reason why Parsortix could not be used to help detect the HER-2 levels in all cancer types.

The Bioview part introduces automation and A.I to quickly detect the HER-2 status of a captured circulating tumour cell (CTC).

All IMHO.

Up 10.2% now!

is significant as I said.

The sp has moved up steadily all day.

School finishes. Would have us believe she holds some. What a joke that is.

Up 8.16% USA money?

The bottom line is these Companies who now have drugs that can home in on HER-2 positive cancers desperately need a way to find out what the HER-2 status of a persons cancer is before, during and after treatment. Angle Plc are working on just that.

All IMHO.

Astrazeneca have got FDA approval (so they can be used in the USA) for a treatment that targets cancers that are HER2-positive (IHC 3+). From the Astrazeneca RNS:-

"AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior systemic treatment and have no satisfactory alternative treatment options.".

From Angle's announcement also this morning:-

"The combination of ANGLE's Parsortix system for harvesting CTCs for analysis, BioView's imaging and analysis technologies, and the new HER2 CTC staining kit under development is intended to provide an easy to use assay based on a simple blood test, providing an up-to-date HER2 status for breast cancer patients on a repeat basis.".

So AstraZeneca, and indeed any Company in the World who's cancer drug targets HER-2 need to know the patients HER-2 status to see if that are suitable and monitor it over time as treatment is given. Angle's contract with Eisai announced by Angle on 2nd Jan is also relevant. See links below.

https://www.lse.co.uk/rns/AZN/enhertu-approved-in-us-for-her2-solid-tumours-d992ucbs0xpl3ik.html

https://www.lse.co.uk/rns/AGL/parsortix-her2-assay-showcased-at-aacr-2024-4k393y7ivsvtwno.html

https://www.lse.co.uk/rns/AGL/contract-announcement-with-eisai-inc-49aplx5us0gzg6h.html

All IMHO.

To Agl?". It seems to me better ways of testing the HER2 status of cancers are desperateky needed so the people these drugs might benefit can be identified. Angle's announcement this morning shows they are making good progress in this area. Hopefully the likes of Astrazeneca are keeping an eye.......

https://www.lse.co.uk/rns/AZN/enhertu-approved-in-us-for-her2-solid-tumours-d992ucbs0xpl3ik.html

Current ways to have a PD-L1 test. See link below.

"There are many ways to do a biopsy. The type of biopsy you have depends on the type of cancer you have and where the tumor is located. In general, a biopsy may be done using:

A hollow needle inserted through your skin. Imaging tests, such as ultrasound, may be used to guide the needle:

1. A fine needle aspiration biopsy uses a very thin needle to remove a sample of cells and/or fluid.

2. A core needle biopsy uses a larger needle to remove a sample.

3. Surgery. Surgery may be done to remove a sample of tissue (an incisional biopsy). In certain cases, the entire tumor will be removed (an excisional biopsy).

4. A scope. Scopes are tools for looking inside your body. They may be inserted through an opening in your body or through a small incision (cut). Special tools may be used with a scope to remove a tissue sample. Examples of scope procedures include bronchoscopy, laparoscopy, colposcopy, and cystoscopy (to examine the inside of the bladder).".

https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/

Until now?

https://www.lse.co.uk/rns/AGL/launch-of-pd-l1-test-to-support-cancer-studies-o8m4cvtjt6ft9a9.html

All IMHO.

"Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial". "First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial". The drug targets the PD-L1 protein!!! On 09 November 2023 Angle announced they have developed an assay to test the PD-L1 status of a persons cancer Circulating Tumour Cells (CTC's) captured by their Parsortix machine. "ANGLE's Portrait PD-L1 test uses CTCs harvested from the Parsortix system to investigate real-time patient PD-L1 status for clinical studies. The test is designed for highly accurate, repeatable, and precise results for CTC PD-L1 biomarker expression.". There appears to be a huge potential market for use in future clinical studies plus eventually it could be used to find which cancer patients are suitable candidates for drugs like Astra's Imfinzi at the cancer treatment clinics.

================

Imfinzi 

Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.

==============

https://www.lse.co.uk/rns/AZN/imfinzi-improved-os-pfs-in-limited-stage-sclc-73j5pms6t7uuuuu.html

All IMHO.

That was meant for HE1. I's asked for ot to be deleted from this AGL board.

Hello.

- excuse the pun!

Nice profit though!..

Nice profit though!

Up 34% Ask 0.36p

Agree.